Background Late-onset systemic lupus erythematosus (LOSLE) is a disease-specific subgroup, which begins clinically after 50 years of age. LOSLE may have unusual clinical and laboratory characteristics, which may delay the diagnosis and timely treatment of the disease.
Objectives To determine the clinical, serological and immunogenetic (HLA-DRB1) differences among patients with LOSLE versus SLE starting at younger ages.
Methods Cross-sectional study in a Colombian population of individuals with SLE according to ACR criteria. Clinical and serological variables were analyzed in 98 patients with LOSLE and 72 patients with early-onset lupus. The HLA-DRB1 genotyping was analyzed in 62 samples from patients with LOSLE and 179 samples from patients without autoimmune disease.
Results Table 1 show the statistically significant clinical and laboratory findings between patients LOSLE vs. early-onset SLE. In patients with LOSLE, the HLA DR17 (DR3) was found more frequently compared to individuals without autoimmune disease (OR 3.81 - 95% CI 1.47 to 10.59) (p=0.0016).
Conclusions In the Colombian population with SLE, there is a probable association between various clinical and serological features, which differentiate the beginning of disease among patients with late-onset SLE vs. early-onset SLE.
Appenzeller S, Pereira DA, Costallat LT. Greater accrual damage in late-onset systemic lupus erythematosus: a long-term follow-up study. Lupus. 2008 Nov;17(11):1023-8.
Boddaert J, Huong DL, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004 Nov;83(6):348-59.
Lalani S, Pope J, de Leon F, Peschken C; Members of CaNIOS/1000 Faces of Lupus. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol. 2010 Jan;37(1):38-44.
Padovan M, Govoni M, Castellino G, Rizzo N, Fotinidi M, Trotta F. Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int. 2007 Jun;27(8):735-41.
Disclosure of Interest None Declared